Victoza for weight loss: what TikTok gets wrong about liraglutide

What did @twinkiemamis actually say?

The creator documented herself doing a weekly Victoza (liraglutide) injection, noting she had just eaten "majority of the apple" and wasn't very hungry. She mentioned this was week two of her journey, referenced a 4mm needle tip, and admitted significant anxiety around injections. She also said her sister does a once-weekly shot, which she envied.

To be clear: this video is not a medical tutorial. It is a personal experience share with a lot of profanity and relatable nervousness. The creator does not make sweeping clinical claims. What she does do is normalize self-injection of a GLP-1 medication, reference dosing frequency, and frame reduced appetite as a positive sign of the drug working. Each of those points deserves some scrutiny.

Does the science back this up?

On reduced appetite after starting liraglutide, yes, the evidence is solid. The mechanism is well-established and the clinical data is not ambiguous here.

Liraglutide works primarily by activating GLP-1 receptors in the hypothalamus and brainstem, slowing gastric emptying and suppressing appetite signals. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3.0 mg daily produced an average 8.4% body weight loss over 56 weeks versus 2.8% with placebo, largely attributed to reduced caloric intake driven by appetite suppression. The creator saying she "ate an apple" and wasn't hungry is consistent with what liraglutide does pharmacologically in early weeks of treatment.

However, Victoza is FDA-approved for type 2 diabetes management, not weight loss. The 3.0 mg dose branded as Saxenda is the approved weight-loss formulation. Using Victoza off-label for weight loss is not uncommon, but it is a clinical distinction that matters and the video does not address it at all.

What did they get wrong (or right)?

The creator said her sister does her injection "once a week," which she frames as preferable. This is almost certainly a reference to semaglutide (Ozempic or Wegovy), not liraglutide. Victoza is dosed daily, not weekly. This is not a minor detail. Confusing daily and weekly GLP-1 dosing schedules is a real medication safety issue.

Accidental weekly dosing of a daily drug like liraglutide could mean missed therapeutic effect; accidental daily dosing of a weekly drug like semaglutide could mean serious overdose risk including severe nausea, vomiting, and hypoglycemia in diabetic patients. The FDA has documented GLP-1 dosing errors in its MedWatch system, and a 2023 safety communication from the Institute for Safe Medication Practices specifically flagged confusion between daily and weekly GLP-1 agents as an emerging harm pattern.

What she got right: the 4mm needle tip she references is consistent with current clinical guidance. A 2015 consensus statement from the Forum for Injection Technique recommended 4mm pen needles for subcutaneous injection in most adults regardless of BMI, citing equivalent glycemic outcomes with lower injection-site pain and reduced risk of intramuscular injection.

What should you actually know?

If you are watching this video and thinking about starting a GLP-1 medication, here is what the creator did not cover.

• Daily vs. weekly matters enormously. Liraglutide (Victoza, Saxenda) is injected daily. Semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) are weekly. These are not interchangeable schedules, and mixing them up has documented safety consequences.
• Injection site rotation is not optional. The creator mentions alternating sides, which is correct. Repeated injection into the same site causes lipohypertrophy, a localized fat buildup that impairs drug absorption. A 2016 study by Blanco et al. in Diabetes Care found lipohypertrophy in 41% of insulin users who did not rotate sites, with measurable impact on glycemic control. The same principle applies to GLP-1 pens.
• Reduced appetite is expected, not a reason to skip meals entirely. Eating "majority of an apple" as a meal is not a medically supervised eating pattern. GLP-1-associated nausea and appetite suppression can lead to inadequate protein and micronutrient intake, particularly in rapid weight loss contexts.
• Victoza is not FDA-approved for weight loss. Off-label use happens and is legal, but it means your prescriber is making a judgment call outside the approved indication. That is a conversation to have explicitly with your provider, not something to infer from a TikTok.

The bottom line

This video is not dangerous misinformation. It is an honest, unpolished personal account that happens to contain one significant factual error about dosing frequency and several gaps in clinical context. The creator's anxiety about needles is relatable and her appetite suppression experience is pharmacologically consistent. But 34,000 viewers watching someone casually confuse daily and weekly GLP-1 schedules is a genuine public health concern, even if unintentional.